The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Evaluating the impact of tisa-cel in NHL
Meryl D. Colton, MD, University of Colorado, Denver, CO, provides an overview of the effects tisagenlecleucel (tisa-cel), a recently approved chimeric antigen receptor (CAR) T-cell therapy, has on the non-Hodgkin lymphoma (NHL) treatment landscape. Tisa-cel has enabled durable responses in heavily pre-treated patients who have received 3-4 prior lines of therapy. Current trials are assessing whether the CAR T-cell therapy can be administered in earlier lines of therapy before autologous stem cell transplantation. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
